MR imaging assessment of experimental hepatic dysfunction with mn‐DPDP

Coley, Brian D.; Mattrey, Robert F.; Baker, Kristine G.; Peterson, Thomas; Burgan, Anthony R.

doi:10.1002/jmri.1880050105

Cited by 10 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy results for the delayed (4 and 24 hours post injection) imaging trial (21) and the safety results for both trials (22) are being reported separately. Already reported elsewhere are the efficacy results from nonclinical studies (5, 23–44) and phases I (6, 45–47) and II (8–18, 48–57) and European phase III 25, 56, 58–65 clinical studies.…”

mentioning

confidence: 99%

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

Federle

Chezmar

Rubin

et al. 2000

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

mentioning

confidence: 99%

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

Federle

Chezmar

Rubin

et al. 2000

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

Evaluation of the hepatocyte‐specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model

Marzola

Maggioni

Vicinanza

et al. 1997

Magnetic Resonance Imaging

View full text Add to dashboard Cite

This work was conducted to test the hypothesis that contrast-enhanced MRI with hepatocyte-specific contrast agents facilitates quantitation and mapping of diffuse liver diseases such as hepatitis and cirrhosis. Gadobenate dimeglumine (Gd-BOPTA/Dimeg, Bracco SpA, Millano, Italy) is a new paramagnetic hepatocyte-specific contrast agent currently undergoing clinical trials. We have assessed the usefulness of gadobenate dimeglumine for the diagnosis of diffuse liver diseases in a rat model of chemically induced hepatitis. The study was based on the measurements of in vivo liver relaxation times as well as on the acquisition of standard SE images. Acute hepatitis considerably reduced the degree of T1 shortening of liver parenchyma caused by intravenous injection of .25 mmol/kg of gadobenate dimeglumine. Analogously, the enhancement of the MRI signal intensity of the liver of rats with hepatitis observed in T1-weighted spin-echo (SE) images was inferior, in terms of both strength and duration, to that recorded in control rats at doses of .25 mmol/kg and .075 mmol/kg of gadobenate dimeglumine. Our results show that gadobenate dimeglumine-enhanced MR imaging has the potential for visualization of hepatitis and for assessment of liver function. Our conclusions differ from those previously published on this subject by other authors. The reasons that led to differing conclusions are discussed.

show abstract

Experimental hepatic dysfunction: Evaluation by MRI with Gd‐EOB‐DTPA

Kim

Murakami

Hasuike

et al. 1997

Magnetic Resonance Imaging

View full text Add to dashboard Cite

To investigate the potential of gadolinium (Gd)-ethoxybenzyl (EOB)-diethylenetriamine-pentaacetic acid (DTPA) for evaluating liver function, chemically induced hepatitis animal models were studied. The rats in group 1 underwent intraperitoneal administration of 2.0 ml/kg and those in group 2 underwent intraperitoneal administration of .5 ml/kg of 50% (V/V) carbon tetrachloride (CCl4) solution. The rats in group 3 served as controls. For rats of each group, the signal intensity of the liver was measured on T1-weighted spin-echo MR images acquired before and until 60 minutes after an intravenous injection of Gd-EOB-DTPA. The remaining rats in each group underwent indocyanine green test, serologic examination, or measurement of prothrombin time. Liver enhancement was compared with results of the other examinations. The degree of liver enhancement with Gd-EOB-DTPA was decreased and the washout of contrast was prolonged in the CCl4-administered groups. In this animal model, both hepatic dysfunction and liver enhancement were dose-dependent. MRI with Gd-EOB-DTPA has the potential to evaluate hepatic function.

show abstract

MR imaging assessment of experimental hepatic dysfunction with mn‐DPDP

Cited by 10 publications

References 15 publications

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

Evaluation of the hepatocyte‐specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model

Experimental hepatic dysfunction: Evaluation by MRI with Gd‐EOB‐DTPA

Contact Info

Product

Resources

About